PharmaEngine, Inc. (TWO:4162) to present our oral and brain-penetrating CHK1 inhibitor PEP07 and MTA-cooperative PRMT5 inhibitor PE-0260 by posters in the American Association of Cancer Research (AACR) Annual Meeting 2025.

 

The posters will showcase:

·       “Preclinical and Clinical Studies of PEP07, a Novel Brain Penetrating Oral CHK1 Inhibitor, on Solid Tumor Treatments”

·       “Preclinical and Clinical Studies of PEP07, a Novel Brain Penetrating Oral CHK1 Inhibitor, on AML and MCL Treatments”

·       “PE-0260, an Oral Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor, Drives Tumor Regressions in MTAP-Deleted Solid Tumors”

 

For more information, please visit AACR 2025 website: https://www.aacr.org/meeting/aacr-annual-meeting-2025/
 

* * *

 

About PharmaEngine, Inc

PharmaEngine, Inc., headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model” to reduce potential risks during the process of new drug development. PharmaEngine has one commercial oncology drug, ONIVYDE®, which has received marketing approvals in many countries worldwide. In addition, one of our projects on the pipeline, PEP07, which is a checkpoint kinase 1 (CHK1) inhibitor that targets the DNA Damage Response (DDR) pathway, is currently undergoing Phase 1 clinical trials. Another ongoing project, PEP08, an MTA-cooperative PRMT5 inhibitor, is currently IND ready. PharmaEngine also conducts, collaborates or licenses-in early-stage new drug discovery and development projects. With extensive experience in drug development and project management, we advance and expand our pipeline, and accelerate drug development and the subsequent commercialization of new medicines.

 

Media Contact: ChiHsing Chang, Spokesperson/Vice President (info@pharmaengine.com)